However, when hyperinsulinemia is the primary defect that triggers insulin resistance, as proposed in the alternative model, therapeutic strategies should primarily focus on reducing plasma insulin concentrations to improve metabolic control and long-term outcomes [26]. The gene discussed is INS; the disease is hyperinsulinism.